Report: Pfizer bids on Sobi; Bellicum buys into TCR;

@FierceBiotech: ICYMI yesterday: Kythera bags FDA approval for its double-chin-shrinking shot. Report | Follow @FierceBiotech

@JohnCFierce: To restate: T-Vec panel demonstrates just how accepting the FDA and its panels are when it comes to "meh" cancer drugs. (Once owned a VTec) | Follow @JohnCFierce

@DamianFierce: Wasn't it odd that $SNTA said Whitaker's new job "allows her to be located closer to her family" in its PR? | Follow @DamianFierce

> Pfizer ($PFE) is the mystery bidder described in Sobi's terse disclosure earlier this week, according to Reuters, eyeing the Swedish drugmaker for a deal that would likely exceed $5 billion. News

> CAR-T player Bellicum Pharmaceuticals ($BLCM) has licensed some TCR technology from the Netherlands' Leiden University Medical Center, investing in a complementary immuno-oncology platform. More

> Chinese CRO WuXi PharmaTech ($WX) is considering going private, entertaining a buyout offer from its CEO and investor Ally Bridge Group. Item

Medical Device News

@FierceMedDev: ICYMI: Kleiner Perkins backs Rapid Micro Biosystems in $25M for microbial detection in quality control. Report | Follow @FierceMedDev

@VarunSaxena2: Drug testing company Cordant raises $12.8M as it seeks to be fragmented industry's one-stop shop. FierceDiagnostics story | Follow @VarunSaxena2

@EmilyWFierce: Researchers Yale used gene editing tech to fix a mutation commonly linked to cystic fibrosis. FierceBiotechResearch article | Follow @EmilyWFierce

> Boston Sci courts hospitals with a pair of deals to boost patient outcomes and lower costs. Story

> Harvard point-of-care handheld cancer diagnostic spinoff WaveGuide raises $13.9M. Report

Pharma News

@FiercePharma: IDEXX misses earnings target, dampens 2015 forecast. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: GSK licks Nicorette manufacturing problems; 'Minis' are back. FiercePharmaManufacturing report | Follow @EricPFierce

@CarlyHFierce: After topping Q1 estimates, Valeant hikes guidance on Salix buy. ICYMI yesterday | Follow @CarlyHFierce

> Novo's purported CEO-to-be is out the door amid executive reshuffle. More

> Lantus dragged down diabetes, but Sanofi beat on sales, earnings anyway. Article

CRO News

> WuXi's CEO moves to take the CRO private. News

> Icon dampens its outlook despite a strong quarter. Report

> Quintiles scales back its 2015 projections after a mixed quarter. More

> Charles River ticks up its revenue amid a shift in focus. Story

> INC swings to profit and dials up its revenue expectations. Article

Vaccines News

> As California measles cases mounted, so did Merck measles vaccine sales. Item

> 80% leap for Pfizer's U.S. Prevnar sales trounces Q1 estimates. Report

> GSK's shingles candidate more effective than Merck's Zostavax in older adults, study says. Story

> Amgen wins FDA panel nod for T-Vec in melanoma. News

> Final trial results show GSK malaria vaccine's efficacy wanes over time. Article

Pharma Manufacturing News

> FDA wants manufacturers to test APIs in hospital antiseptics. More

> AmerisourceBergen keeps up momentum gained from Walgreens deal. News

> Drug shortages become issue in Teva and Mylan hook-up. Article

> Attix Pharmaceuticals recalls hundreds of APIs from the U.S. News

> Hospira's Rocky Mount warning letter lifted; Pfizer benefits. Story

Pharma Asia News

> India works with Hilleman to help industry avoid waste in vaccines stockpile. Report

> China on standardized quality push for traditional medicines. Story

> Singapore's Temasek piles into Indian pharma to the tune of $567.7M. More

> China devices market set to soar by 2020 as GDP overtakes U.S., report says. Item

> Hospital drug sales noted by Premier Li in China reform push. Article

Suggested Articles

German scientists are targeting a protein-cutting enzyme that many viruses, including the coronavirus COVID-19, need to replicate.

The 100 largest companies trading on the London Stock Exchange have boosted the percentage of women on their boards, but has life sciences kept pace?

In this week's EuroBiotech Report, Bicycle lands Genentech collaboration, GSK inks COVOD-19 adjuvant deal and Grifols buys antibiotic assets.